On 6 November 2026, the European CLL Association (ECLLA) formally raised serious concerns regarding the proposed removal of human normal immunoglobulins (IVIg and SCIg) from the Union List of Critical Medicines as part of the 2026 annual review.

In our submission to the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG), we emphasised:
🔹 The importance of immunoglobulin replacement therapy (IgRT) – For these individuals, IgRT is an important component of supportive CLL care. It is not an optional treatment or simply a means of improving wellbeing: it can help prevent serious infections and their potentially life-threatening consequences.
🔹 The consequences of treatment interruptions – Interruptions or delays in immunoglobulin replacement can leave already immunocompromised patients more vulnerable to recurrent and serious infections.
🔹 The need to protect equitable access across Europe – Removing these medicines from the Union List risks further disadvantaging patients in countries with less resilient supply and healthcare systems.

We therefore strongly encourage the EMA and Member States to retain human normal immunoglobulins on the Union List of Critical Medicines and to ensure that the needs of people living with CLL and other haematological malignancies who develop SID are explicitly recognised in the final assessment.

People living with CLL need access not only to effective treatments for their malignancy but also to the supportive medicines that help manage the complications of their disease and its treatment.

ECLLA remains committed to advocating for equitable access to essential medicines and ensuring the voices of people living with CLL are heard in European healthcare decision-making.

One Europe. Equal Care.
🌐 www.eclla.org

#ECLLA #CLL #PatientAdvocacy #Immunoglobulins #CriticalMedicines #HealthEquity #EuropeanHealthcare #EqualAccess